Lung cancer remains the leading cause of cancer-related death worldwide [1], with non-small cell lung cancer (NSCLC) representing about 85% of all diagnosed lung cancer cases [2]. Recent advancements in computed tomography (CT) screening, coupled with growing public health awareness, have contributed...
Lung cancer is the most common cause of cancer-related deaths worldwide. More than 85% of lung cancer cases are classified as non-small cell lung cancer (NSCLC), with a predicted 5-year survival rate of only about 15.9% [1]. Over the past two decades, multidisciplinary efforts and technological advances...
Epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) therapy has significantly improved clinical outcomes for patients with non-small cell lung cancer (NSCLC), being a standard treatment modality in various guidelines. While notable efficacy has been demonstrated in these NSCLC...
Non-small cell lung cancer (NSCLC) represents the most prevalent subtype of lung cancer, accounting for approximately 85% of all lung cancer cases [1]. It encompasses several histological subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [2]. The etiology of NSCLC...
Mutations in the epidermal growth factor receptor (EGFR) represent a prevalent target in non-small cell lung cancer (NSCLC), with EGFR exon 20 insertion (ex20ins) mutations occurring in approximately 2–3% of cases [1]. These mutations, constituting the third most common EGFR mutation subtype following...